Table 8.

Description and impact of the ERG scenarios

Description of the ERG scenario	Impact of the scenario
Including the results from Roy et al. [14] to the OS NMA	Increase in ICER around £14,000 per QALY gained for RAM + PAC vs BSC compared with the ERG base case
Using direct evidence from the RAINBOW trial and not NMA for the efficacy data	ICER for RAM + PAC compared with PAC increased from the ERG base case of £359,794 per QALY gained to £392,108 per QALY gained
Implementation of time-varying utility values that are directly derived from the RAINBOW trial in the model, instead of a single, uniform utility value for the pre-progression state in all cycles	This resulted in an ICER of £408,223 per QALY gained for RAM + PAC vs PAC

BSC Best supportive care, ERG evidence review group, ICER incremental cost-effectiveness ratio, NMA network meta-analysis, OS overall survival, PAC paclitaxel monotherapy, QALY quality-adjusted life-year, RAM ramucirumab monotherapy, RAM + PAC ramucirumab combination therapy